Ketamine analogue - MIRA Pharmaceuticals

Alternative Names: Ketamir; Ketamir-2

Latest Information Update: 01 Jul 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MIRA Pharmaceuticals
Class Antidepressants; Anxiolytics; Cyclohexanones; Fluorine compounds; Small molecules
Mechanism of Action NMDA receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

24 Jun 2024 Pharmacodynamics and adverse event data from a preclinical study in Depressive disorders released by MIRA Pharmaceuticals
10 Jun 2024 Pharmacodynamics data from a preclinical study in Depressive disorders released by MIRA Pharmaceuticals
20 May 2024 MIRA Pharmaceuticals plans to initiate phase I/II trial for Post traumatic stress disorders depression, and neuropathic pain, including cancer pain in 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com